Evaluating deposited radiation energy amount and collision quantities of small-molecule radiosensitizers through Monte Carlo simulations.
Cancer treatment
Monte Carlo simulation
NVX-108
Radiation therapy
Radiosensitizers
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
received:
05
02
2024
revised:
25
06
2024
accepted:
26
06
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
epublish
Résumé
This study investigates the photon interaction mechanism of various small molecule radiosensitizers, including Hydrogen Peroxide, Nimorazole, 5-Fluorouracil, NVX-108, and others, using the MCNP 6.3 Monte Carlo simulation code. The simulations focused on quantifying the linear attenuation coefficients, mean free path, and accumulation factors of these radiosensitizers, as well as their interactions in a simulated spherical water phantom irradiated with a 100 keV mono-energetic X-ray source. Our findings reveal significant variations in deposited energy, collision events, and mean free path among the radiosensitizers, indicating different efficacy levels in enhancing radiation therapy. Notably, NVX-108 demonstrated the highest energy deposition, suggesting its potential as a highly effective radiosensitizer. The study also examined the individual attenuation properties of these radiosensitizers against energetic photons, with NVX-108 showing the highest attenuation coefficient and a shorter mean free path, further supporting its superior potential in effective radiosensitization. It can be concluded that NVX-108 has higher interaction tendency with the energetic photons comparing other small-molecules under investigation.
Identifiants
pubmed: 39050474
doi: 10.1016/j.heliyon.2024.e33734
pii: S2405-8440(24)09765-2
pmc: PMC11267030
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e33734Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
None.The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Int J Nanomedicine. 2021 Feb 12;16:1083-1102
pubmed: 33603370
Radiother Oncol. 1991;20 Suppl 1:143-9
pubmed: 2020763
Radiother Oncol. 1998 Feb;46(2):135-46
pubmed: 9510041
Int J Mol Sci. 2019 Dec 31;21(1):
pubmed: 31906108
Cancer J. 2013 May-Jun;19(3):200-7
pubmed: 23708066
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):1019-1029
pubmed: 32585332
Biomedicines. 2022 Jul 21;10(7):
pubmed: 35885067
Clin Lung Cancer. 2001 Feb;2(3):182-90; discussion 191-4
pubmed: 14700475
Antioxid Redox Signal. 2014 Jul 10;21(2):260-92
pubmed: 24382094
Radiother Oncol. 2020 Sep;150:225-235
pubmed: 32598976
Oncotarget. 2017 Jun 8;8(37):62742-62758
pubmed: 28977985
Phys Eng Sci Med. 2023 Sep;46(3):1023-1032
pubmed: 37219796
Comput Biol Med. 2023 Oct;165:107356
pubmed: 37688994
J Clin Oncol. 2007 Sep 10;25(26):4043-50
pubmed: 17827452
Cancer Res. 2007 Sep 15;67(18):8791-9
pubmed: 17875720
Anal Cell Pathol (Amst). 2016;2016:6146595
pubmed: 26998418
Signal Transduct Target Ther. 2021 Jul 9;6(1):254
pubmed: 34238917
Transl Cancer Res. 2017 Jul;6(Suppl 5):S822-S839
pubmed: 30613483
Semin Cancer Biol. 2021 Jan;68:230-241
pubmed: 32113999
Indian J Dent Res. 2014 Jan-Feb;25(1):83-90
pubmed: 24748306
Semin Radiat Oncol. 2002 Jul;12(3 Suppl 2):33-6
pubmed: 12174343
Radiat Oncol. 2018 Jun 27;13(1):121
pubmed: 29945636
Mol Clin Oncol. 2022 Mar;16(3):68
pubmed: 35154708
Clin Oncol (R Coll Radiol). 2007 Aug;19(6):397-417
pubmed: 17478086
Oncol Rep. 2008 Jun;19(6):1389-94
pubmed: 18497941
Int J Oncol. 2009 Mar;34(3):609-18
pubmed: 19212665
Indian J Clin Biochem. 2015 Jan;30(1):11-26
pubmed: 25646037
Front Pharmacol. 2023 Feb 16;14:1145551
pubmed: 36873996
Trends Pharmacol Sci. 2018 Jan;39(1):24-48
pubmed: 29224916
Int J Med Sci. 2012;9(3):193-9
pubmed: 22408567
Front Mol Biosci. 2014 Nov 17;1:24
pubmed: 25988165